-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

Benzinga·05/18/2026 17:44:40
Listen to the news
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.